Subclinical myocardial dysfunction by tissue Doppler echocardiography in primary antiphospholipid syndrome: Preliminary results

Imagem de Miniatura
Arquivos
art_LUCENA_Subclinical_myocardial_dysfunction_by_tissue_Doppler_echocardiography_in_2018.PDF (261.24 KB)
Citações na Scopus
0
Tipo de produção
article
Data de publicação
2018
DOI
Scopus
Web of Science
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER SCIENCE BV
Autores
LUCENA, Tarcila Fontes de Lima Gomes
ARAUJO, Roberto Paulo Correia de
CARVALHO, Jozelio Freire de
Citação
EGYPTIAN RHEUMATOLOGIST, v.40, n.1, p.35-38, 2018
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Aim of the work: To preliminary evaluate the myocardiac function in asymptomatic primary antiphospholipid syndrome (PAPS) patients using conventional and tissue Doppler echocardiogram. Patients and methods: Nine female PAPS patients asymptomatic for cardiac manifestations and 7 matched controls were enrolled. Myocardial function was determined by echocardiogram (conventional and tissue Doppler imaging 'TDI' techniques). Results: The median age of the patients was 43 (26-55 years) and disease duration 10 (3-19) years. Traditional cardiovascular risk factors were similar in PAPS and controls. Venous and arterial events were present in 55.6%, 22.2% showed obstetric features, 33.3% had stroke, 44.4% deep venous thrombosis and 66.7% had livedo reticularis. All patients were under oral anticoagulants with international normalization ratio within therapeutic range (2-3). 88.9% were positive for IgG and/or IgM anticardiolipin antibodies and 66.7% were positive for lupus anticoagulant. Conventional echocardiographic data were not altered in all evaluated parameters comparing patients and controls. Regarding TDI, a lower S' (systolic wave which is related to systolic function in the analysed segment) of lateral wall of left ventricle was observed in PAPS in comparison to controls [0.085 (0.007-0.12) vs. 0.12 (0.09-0.13), p = 0.004] as well as A' wave of the septum (related to late diastolic function in the analysed segment) [0.07 (0.06-0.08) vs. 0.09 (0.07-0.11), p = 0.02]. Conclusion: The present study demonstrated subclinical myocardial dysfunction using TDI in asymptomatic PAPS patients. TDI is non-invasive and cost effective. Prospective studies including a large number of participants in order to confirm these preliminary data are needed. (C) 2017 Egyptian Society of Rheumatic Diseases. Publishing services provided by Elsevier B.V.
Palavras-chave
Primary antiphospholipid syndrome, Doppler echocardiography, Asymptomatic, Diastolic dysfunction, Myocardial dysfunction
URI
https://observatorio.fm.usp.br/handle/OPI/26505
Referências
  1. Adler A, 2009, NAT CLIN PRACT CARD, V6, P215, DOI 10.1038/ncpcardio1436
  2. Amengual O., 1998, Annals Academy of Medicine Singapore, V27, P61
  3. Ames PRJ, 2009, J THROMB HAEMOST, V7, P537, DOI 10.1111/j.1538-7836.2009.03308.x
  4. Badawi AIZ, 2017, EGYPT RHEUMATOL, V39, P75, DOI 10.1016/j.ejr.2016.07.001
  5. Birdane A, 2007, ECHOCARDIOGR-J CARD, V24, P485, DOI 10.1111/j.1540-8175.2007.00422.x
  6. Freire Cláudia Maria V., 2007, Arq Bras Endocrinol Metab, V51, P168, DOI 10.1590/S0004-27302007000200005
  7. Gaber W, 2012, EGYPT RHEUMATOL, V34, P51, DOI 10.1016/j.ejr.2012.01.001
  8. Harris EN, 2002, LUPUS, V11, P269, DOI 10.1191/0961203302lu202rr
  9. HASNIE AMA, 1995, AM HEART J, V129, P1009, DOI 10.1016/0002-8703(95)90124-8
  10. Hennekens Charles H, 2006, MedGenMed, V8, P54
  11. HUGHES GRV, 1983, BRIT MED J, V287, P1088, DOI 10.1136/bmj.287.6399.1088
  12. Jara LJ, 2007, CLIN REV ALLERG IMMU, V32, P172, DOI 10.1007/s12016-007-0008-9
  13. Lipsy Robert J, 2003, J Manag Care Pharm, V9, P2
  14. Mandinov L, 2000, CARDIOVASC RES, V45, P813, DOI 10.1016/S0008-6363(99)00399-5
  15. Masugata H, 2009, CLIN EXP HYPERTENS, V31, P400, DOI 10.1080/10641960802668722
  16. Matsuura Eiji, 2009, Curr Rheumatol Rep, V11, P61
  17. Nagueh SF, 1998, CIRCULATION, V98, P1644
  18. Nagueh SF, 1997, J AM COLL CARDIOL, V30, P1527, DOI 10.1016/S0735-1097(97)00344-6
  19. Nagueh SF, 2009, EUR J ECHOCARDIOGR, V10, P165, DOI 10.1093/ejechocard/jep007
  20. Nardi E, 2007, J NEPHROL, V20, P320
  21. Ommen SR, 2000, CIRCULATION, V102, P1788
  22. Raafat HA, 2015, EGYPT RHEUMATOL, V37, P55, DOI 10.1016/j.ejr.2014.07.007
  23. Rakowski H, 1996, J Am Soc Echocardiogr, V9, P736, DOI 10.1016/S0894-7317(96)90076-0
  24. Reshetnyak TM, 2008, TERAPEVT ARKH, V80, P60
  25. Sharp A, 2008, J AM COLL CARDIOL, V52, P1015, DOI 10.1016/j.jacc.2008.04.065
  26. Swaminathan S, 2003, AM J CARDIOL, V91, P570, DOI 10.1016/S0002-9149(02)03308-8
  27. Wilson WA, 1999, ARTHRITIS RHEUM, V42, P1309, DOI 10.1002/1529-0131(199907)42:7<1309::AID-ANR1>3.0.CO;2-F
  28. Wisloff F, 2002, THROMB RES, V108, P263, DOI 10.1016/S0049-3848(02)00400-0
  29. Yip GWK, 2009, HEART, V95, P980, DOI 10.1136/hrt.2008.153551
  30. Zinger H, 2009, CLIN REV ALLERG IMMU, V37, P20, DOI 10.1007/s12016-008-8094-x

Coleções
Artigos e Materiais de Revistas Científicas - HC/ICr
Artigos e Materiais de Revistas Científicas - ODS/03